Wollin M, Abele S, Bruns H, Weyand M, Kalden J, Ensminger SM, Spriewald BM (2009)
Publication Status: Published
Publication Type: Journal article, Original article
Publication year: 2009
Book Volume: 22
Pages Range: 342-9
Journal Issue: 3
DOI: 10.1111/j.1432-2277.2008.00802.x
Experimental and clinical data provide evidence that TNF-alpha contributes to acute and chronic allograft rejection. In this study, we explored the effect of TNF-alpha blockade using the chimeric monoclonal antibody infliximab on the development of transplant arterisoclerosis in a fully mismatched aortic allograft model. Post-transplant treatment of CBA (H2(k)) recipients with 250 mug infliximab (cumulative dose 1.25 mg) reduced luminal occlusion of C57Bl/6 (H2(b)) aortic grafts on day 30 from 77 +/- 5% in untreated controls to 52 +/- 6%. Increasing the dose of anti-TNF-alpha antibody had no further beneficial effect. Treatment with human control immunoglobulin had no effect on intima proliferation. Under TNF-alpha blockade, ICAM-1 and PDGF mRNA expression within the grafts was strongly reduced, whereas iNOS expression was enhanced. The data show that TNF-alpha blockade using infliximab can reduce the development of transplant arteriosclerosis in fully mismatched murine aortic grafts.
APA:
Wollin, M., Abele, S., Bruns, H., Weyand, M., Kalden, J., Ensminger, S.M., & Spriewald, B.M. (2009). Inhibition of TNF-alpha reduces transplant arteriosclerosis in a murine aortic transplant model. Transplant International, 22(3), 342-9. https://doi.org/10.1111/j.1432-2277.2008.00802.x
MLA:
Wollin, Martina, et al. "Inhibition of TNF-alpha reduces transplant arteriosclerosis in a murine aortic transplant model." Transplant International 22.3 (2009): 342-9.
BibTeX: Download